The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets

Autor: Sarah Rose, Ria Fisher, Mark A. Varney, Ronan Depoortère, Atsuko Hikima, Rebecca Morris, Adrian Newman-Tancredi, Michael J. Jackson

Publikováno v: Fisher, R, Hikima, A, Morris, R, Jackson, M J, Rose, S, Varney, M A, Depoortere, R & Newman-Tancredi, A 2020, ' The selective 5-HT 1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets ', Neuropharmacology, vol. 167, 107997 . https://doi.org/10.1016/j.neuropharm.2020.107997
King's College London
Neuropharmacology

l-DOPA is the gold-standard pharmacotherapy for treatment of Parkinson's disease (PD) but can lead to the appearance of troubling dyskinesia which are attributable to ‘false neurotransmitter’ release of dopamine by serotonergic neurons. Reducing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3085a626eb1b59f691bd663fbecf739e
https://kclpure.kcl.ac.uk/en/publications/1e11b8e0-d1b8-4575-878a-9a65a73748ba

The effect of Banisteriopsis caapi (B. caapi ) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease

Autor: Andrew J. Lees, Sarah Rose, Robert C. Hider, Ria Fisher, Louise Lincoln, Vincenzo Abbate, Michael J. Jackson, Peter Jenner

Publikováno v: Fisher, R, Lincoln, L, Jackson, M J, Abbate, V, Jenner, P, Hider, R C, Lees, A & Rose, S 2018, ' The Effect of Banisteriopsis caapi (B. caapi) on the Motor Deficits in the MPTP-treated Common Marmoset Model of Parkinson's disease ', PHYTOTHERAPY RESEARCH, vol. 32, no. 4, pp. 678-687 . https://doi.org/10.1002/ptr.6017

Banisteriopsis caapi (B. caapi) contains harmine, harmaline, and tetrahydroharmine, has monoamine oxidase inhibitory activity, and has reported antiparkinsonian activity in humans when imbibed as a tea; however, its effects are poorly documented. For

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffd59cb2d2682ffb94a45084de017b83
https://doi.org/10.1002/ptr.6017

Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets

Autor: Louise, Lincoln, Ria, Fisher, Michael J, Jackson, Peter, Jenner, John, Neumeyer, Anna W, Sromek, Andrew J, Lees, Sarah, Rose

Publikováno v: Movement disorders : official journal of the Movement Disorder Society. 31(9)

The D1/D2 dopamine agonist apomorphine has poor oral bioavailability, necessitating subcutaneous administration in the treatment of Parkinson's disease (PD). Acute subcutaneous injection is used as rescue therapy from "off" periods, whereas continuou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::799ad9abbf8854e3de0acc7fc1117caa
https://pubmed.ncbi.nlm.nih.gov/27133947